Clinical trials sponsored by Shanghai Henlius Biotech

Phase breakdown

Conditions studied

Recruiting trials led by Shanghai Henlius Biotech

• A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
  NCT07459751 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours
  NCT07533708 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 5 locations
• A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
  NCT07253142 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 10 locations
• A Phase II Study of HLX22 in Combination With Trastuzumab Deruxtecan in HER2-low, Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer Patients
  NCT06832202 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Phase II Study to Evaluate the Efficacy and Safety of HLX43 + Serplulimab as Neoadjuvant Therapy in Subjects With NSCLC
  NCT07269782 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors
  NCT06848699 · Phase: Phase 1, Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 3 locations
• A Study of HLX18 vs. OPDIVO® in Multiple Resected Solid Tumors
  NCT07518043 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 7 locations
• A Study of HLX42 in Advanced/Metastatic Solid Tumors
  NCT06210815 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Study to Evaluate HLX22 in Combination With HLX87 in Patients With HER2-Positive Recurrent or Metastatic Breast Cancer
  NCT07294508 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
  NCT07038382 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 17 locations
• Phase II, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of HLX43 (an Anti-PD-L1 ADC) in Subjects With Advanced Colorectal Cancer
  NCT07106892 · Phase: Phase 2 · Ages: 18 Days to 75 Days · Sex: All (male and female) · 2 locations

Common questions

How many trials is Shanghai Henlius Biotech recruiting for?

Shanghai Henlius Biotech is the lead sponsor of 11 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.